Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo, 113-8677, Japan.
Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, 113-8677, Japan.
BMC Cancer. 2018 Mar 20;18(1):302. doi: 10.1186/s12885-018-4212-1.
Currently, immune checkpoint (ICP) inhibitors are essential drugs for the treatment of non-small cell lung cancer (NSCLC). However, in patients previously treated with ICP inhibitors, the efficacy and safety of re-challenging the same or another ICP inhibitor remain unclear.
We present the case of a patient treated with nivolumab for advanced NSCLC who was previously treated with an ICP inhibitor as the first-line chemotherapy along with heavy cytotoxic chemotherapy. After the failure of five lines of chemotherapy, 3 cycles of nivolumab, as the ICP inhibitor re-challenge, the patient achieved a partial response.
This case might suggest that re-challenging an ICP inhibitor could be clinically active in selected patients with advanced NSCLC who progress after achieving an initial clinical benefit with an ICP inhibitor.
目前，免疫检查点（ICP）抑制剂是治疗非小细胞肺癌（NSCLC）的重要药物。然而，在先前接受 ICP 抑制剂治疗的患者中，再次使用相同或另一种 ICP 抑制剂的疗效和安全性尚不清楚。
我们报告了一例接受纳武利尤单抗治疗晚期 NSCLC 的患者，该患者先前曾接受 ICP 抑制剂作为一线化疗联合重度细胞毒性化疗。在五线化疗失败后，患者接受了 3 个周期的纳武利尤单抗（ICP 抑制剂再挑战）治疗，取得了部分缓解。
该病例提示，对于先前接受 ICP 抑制剂治疗后获得初始临床获益但病情进展的晚期 NSCLC 患者，再次使用 ICP 抑制剂可能具有临床活性。
